Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Truist Securities Reiterates Buy on AbbVie, Raises Price Target to $210

Author: Benzinga Newsdesk | July 26, 2024 08:48am
Truist Securities analyst Robyn Karnauskas reiterates AbbVie (NYSE:ABBV) with a Buy and raises the price target from $195 to $210.

Posted In: ABBV

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist